Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
SIMPLE SUMMARY: The treatment of renal cancer is currently based on the use of antiangiogenic drugs targeting the VEGF-A pathway and/or immunotherapy targeting immune checkpoint inhibitors. Despite combined therapies being approved as first-line treatments, all patients will not benefit from them. W...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776425/ https://www.ncbi.nlm.nih.gov/pubmed/36551652 http://dx.doi.org/10.3390/cancers14246167 |